NCT00044720CompletedPhase 4
An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor
Wyeth is now a wholly owned subsidiary of Pfizer0 sites484 target enrollmentStarted: September 6, 2002Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 484
Study Overview
Brief Summary
The incidence of efficacy failure at 12 months between two regimens.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- None
Eligibility Criteria
- Ages
- 13 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: 13 years or older, 40 kgs or more
- •End-stage renal disease
- •African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft
Exclusion Criteria
- •Evidence of active infection
- •Evidence abnormal chest x-ray
- •Patients with HIV.
Investigators
Similar Trials
Completed
Phase 2
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsAsthmaNCT01479621Teva Branded Pharmaceutical Products R&D, Inc.909
Completed
Phase 2
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult PatientsTuberculosisTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDRDrug-Resistant TuberculosisNCT03338621Global Alliance for TB Drug Development455
Active, not recruiting
Phase 1
Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease.EUCTR2011-002452-13-GBGlaxoSmithKline Research & Development Ltd3,161
Active, not recruiting
Phase 1
Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma.AsthmaEUCTR2011-005553-31-GBGlaxoSmithKline Research & Development Ltd4,233
Terminated
Phase 2
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term ExtensionLiver Transplant RejectionNCT03781414Novartis Pharmaceuticals129